THR 317

Drug Profile

THR 317

Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB-403; THR-317; αPlGF

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BioInvent International; ThromboGenics
  • Developer BioInvent International; Oncurious; Roche; ThromboGenics
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Placenta growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I/II Medulloblastoma
  • Preclinical Diabetic retinopathy
  • No development reported Age-related macular degeneration; Glioblastoma; Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 17 Jan 2017 THR 317 receives Orphan Drug status for Medulloblastoma in European Union
  • 16 Jan 2017 EMA Committee for Orphan Medicinal Products issues positive opinion on orphan drug designation for THR 317 in the European Union for Medulloblastoma before January 2017
  • 10 Jan 2017 Phase-II clinical trials in Diabetic macular oedema in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top